| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9328423 | Gynecologic Oncology | 2005 | 5 Pages |
Abstract
Somatic AGO mutations are infrequent in primary ovarian cancers and are unlikely to contribute to familial ovarian cancer. Reconstitution experiments, rather than measuring tumor levels of cyclin E and c-Myc, provide an effective approach to determine the functional significance of AGO mutations identified in human cancers.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Eunice L. Kwak, Kenneth H. Moberg, Doke C.R. Wahrer, Jennifer E. Quinn, Paula M. Gilmore, Colin A. Graham, Iswar K. Hariharan, D. Paul Harkin, Daniel A. Haber, Daphne W. Bell,